Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective is to determine the efficacy of 2 treatment regimens of daratumumab, as measured by the overall response rate (ORR) (complete response [CR] + partial response [PR]), in subjects with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD.
Inclusion criteria
- Multiple myeloma